Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset
Authors:
- 1 November 2021
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 910, 174452
Abstract
No abstract availableKeywords
Funding Information
- Natural Sciences and Engineering Research Council of Canada
- Biogen
- Santé
- Weston Brain Institute
- Parkinson Canada
- Michael J. Fox Foundation for Parkinson's Research
- AbbVie Canada
This publication has 74 references indexed in Scilit:
- Nicotinic excitation of serotonergic projections from dorsal raphe to the nucleus accumbensJournal of Neurophysiology, 2011
- Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) EnantiomersIn Vitroand in the MPTP-Lesioned Primate:R-MDMA Reduces Severity of Dyskinesia, WhereasS-MDMA Extends Duration of ON-TimeJournal of Neuroscience, 2011
- GlyT1 − Up from the Ashes. The Importance of Not Condemning a Mechanism Based on a Single ChemotypeACS Chemical Neuroscience, 2010
- The glycine transport inhibitor sarcosine is an NMDA receptor co‐agonist that differs from glycineThe Journal of Physiology, 2009
- Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonismMovement Disorders, 2008
- Modulation of Striatal Dopamine Release by Glycine Transport InhibitorsNeuropsychopharmacology, 2005
- Pharmacology and expression analysis of glycine transporter GlyT1 with [3H]-(N-[3-(4′-fluorophenyl)-3-(4′phenylphenoxy)propyl])sarcosineNeuropharmacology, 2003
- N[3‐(4′‐fluorophenyl)‐3‐(4′‐phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transportBritish Journal of Pharmacology, 2001
- Binding of antipsychotic drugs to human brain receptorsLife Sciences, 2000
- Direct and indirect presynaptic control of dopamine release by excitatory amino acidsAmino Acids, 1998